SCI

16March

PrognosticimpactofKRASG12CmutationinpatientswithNSCLC

FinnSP,AddeoA,DafniU,etal.PrognosticimpactofKRASG12CmutationinpatientswithNSCLC:resultsfromtheETOPLungscapeProject.JThoracOncol.

Correspondenceto:StephenP.Finn,CancerMolecularDiagnosticsLaboratory,CentralPathologyLaboratory(CPL)Building,LabMedDirectorate,St.JamessHospital,Dublin8,Ireland.Email:stephen.finn

KRASmutations,themostfrequentgain-of-functionalterationsinnon-smallcelllungcancer(NSCLC),arecurrentlyemergingaspotentialpredictivetherapeutictargets.KRAS-G12C(Kr_G12C)roleisofspecialinterest,followingtherecentdiscoveryandpreclinicalanalysesoftwodifferentKr_G12Ccovalentinhibitors(AMG-,MRTX).

KRAS突变是非小细胞肺癌(NSCLC)中最常见的功能性改变，目前正在成为潜在的预测性治疗靶点。在最近，研究者们发现和临床前分析了两种不同的Kr_G12C共价抑制剂之后，KRAS-G12C(Kr_G12C)的作用引起了特别的兴趣。

KRASmutationswereassessedinFFPEtissuesectionsbyamicrofluidics-basedmultiplexPCRplatformasa